Wandercraft·· 2025-11-03AI 评分54
Wandercraft Atalante X 获 FDA 第二次适应症扩展，覆盖 C4-L5 脊髓损伤与多发性硬化患者
Wandercraft Gains Second FDA Indication Extension for Atalante X in Less Than Two Years, Extending Advanced Robotic Rehabilitation for More Patients with Severe Mobility Loss
AI 导读
Wandercraft 宣布其自平衡外骨骼 Atalante X 获得 FDA 适应症扩展许可，适用范围从脊髓损伤 T5-L5 扩展至 C4-L5，并新增多发性硬化适应症。
来源：Wandercraft · wandercraft.eu